A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Principal Investigator

Jacqueline Vuky

Study Purpose

This study is being done to test the good and bad effects of BLU-667 in men and women with non-small cell lung cancer, thyroid cancer and other advanced solid tumors.

Medical Condition(s)

Non small cell lung cancer (NSCLC)
Thyroid cancer
Advanced Solid Tumors

Eligibility Criteria

1. Men and women 18 years or older
2. Recurrent or metastatic solid tumors
3. Adequate organ function
4. Other criteria apply

Age Range

18 - 100

Healthy Volunteers Needed


Duration of Participation

Participants will receive the study drug as long as their cancer does not get worse and they do not develop side effects that they cannot tolerate. After the last dose of the study drug, participants will have a follow-up visit 30 days after finishing drug. If a patient comes off study before disease progression, long term follow-up will be conducted every 3 months until the end of the study, a new treatment has been initiated, disease progression or study has been ended by sponsor, which is planned to be in three years.

Minors Included



Knight Clinical Trials Information Line


Recruitment End


Compensation Provided


Go Back